SG11201907701YA - Composition and method for preventing or delaying onset of myopia comprising atropine - Google Patents
Composition and method for preventing or delaying onset of myopia comprising atropineInfo
- Publication number
- SG11201907701YA SG11201907701YA SG11201907701YA SG11201907701YA SG11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- myopia
- preventing
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
100 76 25 w r o sA sza .4\ F10, 3A 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT o mono VIII °nolo OH 100 Ho Ho Ho 110 111110 oimIE (10) International Publication Number WO 2018/154440 Al (51) International Patent Classification: A61K 31/46 (2006.01) A61P 27/10 (2006.01) (21) International Application Number: PCT/IB2018/051039 (22) International Filing Date: 20 February 2018 (20.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/461,723 21 February 2017 (21.02.2017) US (71) Applicant: SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; The Academia, 20 College Road, Discovery Tower Level 6, Singapore 169856 (SG). (72) Inventors: TAN, Donald Tiang Hwee; 49 Oei Tiong Ham Park, Singapore 267054 (SG). CHIA, Audrey; 205a Tembeling Road, Singapore 423699 (SG). BEUERMAN, Roger; 1 St. Thomas Walk, 14-02, Singapore 238096 (SG). VELUCHAMY, Amutha Barathi; 25, Springtide Place, Singapore 786428 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE (54) Title: COMPOSITION AND METHOD FOR PREVENTING OR DELAYING ONSET OF MYOPIA COMPRISING AT- ROPINE (57) : Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461723P | 2017-02-21 | 2017-02-21 | |
PCT/IB2018/051039 WO2018154440A1 (en) | 2017-02-21 | 2018-02-20 | Composition and method for preventing or delaying onset of myopia comprising atropine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907701YA true SG11201907701YA (en) | 2019-09-27 |
Family
ID=63253608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907701YA SG11201907701YA (en) | 2017-02-21 | 2018-02-20 | Composition and method for preventing or delaying onset of myopia comprising atropine |
Country Status (10)
Country | Link |
---|---|
US (1) | US11253507B2 (en) |
EP (1) | EP3585386A4 (en) |
JP (2) | JP2020509085A (en) |
KR (1) | KR20200007769A (en) |
CN (1) | CN110545813A (en) |
AU (1) | AU2018224426B2 (en) |
NZ (1) | NZ756936A (en) |
PH (1) | PH12019501945A1 (en) |
SG (1) | SG11201907701YA (en) |
WO (1) | WO2018154440A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
WO2016196367A1 (en) | 2015-05-29 | 2016-12-08 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
CN115835905A (en) * | 2020-06-02 | 2023-03-21 | 纽约市哥伦比亚大学理事会 | Methods and compositions for the prevention and treatment of myopia using selective histamine H1-receptor antagonists levocabastine and its derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
WO2012161655A1 (en) * | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
CN109310687B (en) | 2016-05-25 | 2023-10-20 | 新加坡保健服务集团 | Aqueous composition containing atropine |
-
2018
- 2018-02-20 AU AU2018224426A patent/AU2018224426B2/en active Active
- 2018-02-20 CN CN201880025791.XA patent/CN110545813A/en active Pending
- 2018-02-20 JP JP2019566000A patent/JP2020509085A/en not_active Withdrawn
- 2018-02-20 WO PCT/IB2018/051039 patent/WO2018154440A1/en unknown
- 2018-02-20 KR KR1020197027649A patent/KR20200007769A/en not_active IP Right Cessation
- 2018-02-20 SG SG11201907701YA patent/SG11201907701YA/en unknown
- 2018-02-20 EP EP18756627.8A patent/EP3585386A4/en active Pending
- 2018-02-20 US US16/487,423 patent/US11253507B2/en active Active
- 2018-02-20 NZ NZ756936A patent/NZ756936A/en unknown
-
2019
- 2019-08-22 PH PH12019501945A patent/PH12019501945A1/en unknown
-
2021
- 2021-12-27 JP JP2021211859A patent/JP2022046673A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018154440A1 (en) | 2018-08-30 |
CN110545813A (en) | 2019-12-06 |
US11253507B2 (en) | 2022-02-22 |
AU2018224426B2 (en) | 2023-05-18 |
JP2022046673A (en) | 2022-03-23 |
JP2020509085A (en) | 2020-03-26 |
NZ756936A (en) | 2022-11-25 |
AU2018224426A1 (en) | 2019-09-26 |
KR20200007769A (en) | 2020-01-22 |
PH12019501945A1 (en) | 2020-07-06 |
EP3585386A1 (en) | 2020-01-01 |
US20200138801A1 (en) | 2020-05-07 |
EP3585386A4 (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201909602TA (en) | Compositions and methods involving probiotic molecules | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201811329UA (en) | Spheroids including biologically-relevant materials and related methods | |
SG11202000125TA (en) | Apparatus and methods for imaging | |
SG11201906616VA (en) | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201910053YA (en) | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies | |
SG11201909568UA (en) | Reprogramming of a differentiated cell to an undifferentiated cell using exosome |